Role of malignant ascites on human mesothelial cells and their gene expression profiles

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Matte, Isabelle ^a   Lane, Denis ^a   Bachvarov, Dimcho ^b   Rancourt, Claudine ^a   Piché, Alain ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 8; LYSOPHOSPHATIDIC ACID; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; BMP2 GENE; CANCER CELL; CANCER GROWTH; CASE REPORT; CELL ASSEMBLY AND ORGANIZATION; CELL CYCLE; CELL DEATH; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CELLULAR PARAMETERS; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IL 8 GENE; INFLAMMATION; INHBA GENE; IRS2 GENE; KTR 18 GENE; MALIGNANT ASCITES; MESOTHELIUM CELL; OVARY CANCER; PARACRINE SIGNALING; PHLDA1 GENE; PTHLH GENE; REAL TIME POLYMERASE CHAIN REACTION; ASCITES; COMPLICATION; EPITHELIUM CELL; GENETICS; MESOTHELIOMA; METABOLISM; OVARY TUMOR; PATHOLOGY; PERITONEAL CAVITY; TUMOR MICROENVIRONMENT;

APOPTOSIS; ASCITES; CELL PROLIFERATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, MESOTHELIAL; OVARIAN NEOPLASMS; PERITONEAL CAVITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899958930     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-288     Document Type: Article

References (34)

1. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 1999, 49:297-320. 10.3322/canjclin.49.5.297, 11198956.
2. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 2013, 13:273-282. 10.1038/nrc3432, 23426401.
3. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9:415-428. 10.1038/nrc2644, 2814299, 19461667.
4. Lane D, Matte I, Rancourt C, Piché A. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer. J Ovarian Res 2010, 3:1. 10.1186/1757-2215-3-1, 2821314, 20157422.
5. Matte I, Lane D, Laplante C, Rancourt C, Piché A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2012, 2:566-580. 3433103, 22957308.
6. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003, 3:582-591. 10.1038/nrc1143, 12894246.
7. Lane D, Robert V, Grondin R, Rancourt C, Piché A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007, 121:1227-1237. 10.1002/ijc.22840, 17534891.
8. Lane D, Goncharenko-Khaider N, Rancourt C, Piché A. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010, 29:3519-3531. 10.1038/onc.2010.107, 20400979.
9. Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer 2012, 11:84. 10.1186/1476-4598-11-84, 3526430, 23158473.
10. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007, 9:820-829. 10.1593/neo.07472, 2040209, 17971902.
11. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990, 86:851-855. 10.1172/JCI114784, 296802, 2394835.
12. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, Kuwabara A, Yanagita Y, Ikeya T, Tanahashi Y, Ogawa T, Ohwada S, Morishita Y, Ohta H, Im DS, Tamoto K, Tomura H, Okajima F. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 2004, 279:6595-6605.
13. Davidson B. Malignant effusions: from diagnosis to biology. Diagn Cytopathol 2004, 31:246-254. 10.1002/dc.20133, 15452897.
14. Na D, Lv ZD, Liu FN, Xu Y, Jiang CG, Sun Z, Miao ZF, Li F, Xu HM. Transforming growth factor β1 produced in autocrine/paracrine manner affects the morphology and function of mesothelial cells and promotes peritoneal carcinomatosis. Int J Mol Med 2010, 26:325-332.
15. Ikubo A, Morisaki T, Katano M, Kitsuki H, Anan K, Uchiyama A, Tanaka M, Torisu M. A possible role of TGF-β in the formation of malignant effusions. Clin Immunol Immunopathol 1995, 77:27-32. 10.1016/0090-1229(95)90133-7, 7554479.
16. Zhang H, Liu X, Liu Y, Yi B, Yu X. Epithelial-mesenchymal transition of rat peritoneal mesothelial cells via RhoA/Rock pathway. In Vitro Cell Dev Biol Anim 2011, 47:165-172. 10.1007/s11626-010-9369-0, 21108050.
17. Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Possible involvement of SDF-1α/CXCR4-DPPIV axis in TGF-β1-induced enhancement of migratory potential in human peritoneal mesothelial cells. Cell Tissue Res 2007, 330:221-229. 10.1007/s00441-007-0455-x, 17846797.
18. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000, 36:341-347. 10.1046/j.1365-2559.2000.00770.x, 10759948.
19. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003, 63:912-916.
20. Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evan CA, Coleman RE, Holen I. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004, 86:269-279.
21. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526. 10.1158/1078-0432.CCR-07-2223, 18451212.
22. Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996, 22:237-239. 10.1016/S0748-7983(96)80009-6, 8654603.
23. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites : a retrospective study. Ann Oncol 2007, 18:945-949. 10.1093/annonc/mdl499, 17298959.
24. Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res 2009, 19:156-172. 10.1038/cr.2009.5, 19153598.
25. Kazi JU, Vaapil M, Agarwal S, Bracco E, Pahlman S, Rönnstrand L. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cell Signal 2013, 25:1852-1860. 10.1016/j.cellsig.2013.05.016, 23707526.
26. Shen Z, Wu M, Elson P, Kennedy AW, Belinson J, Casey G, Xu Y. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol 2001, 83:25-30. 10.1006/gyno.2001.6357, 11585410.
27. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998, 280:719-723. 10.1001/jama.280.8.719, 9728644.
28. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998, 9:437-442. 10.1023/A:1008217129273, 9636836.
29. Mills GB, May C, McGill M, Roifman CM, Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 1988, 48:1066-1071.
30. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995, 309:933-940. 1135721, 7639713.
31. Zeliadt NA, Mauro LJ, Wattenberg EV. Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3. Toxicol Appl Pharmacol 2008, 232:408-417. 10.1016/j.taap.2008.08.007, 2581931, 18771677.
32. Nomura M, Shiiba K, Katagiri C, Kasugai I, Masuda K, Sato I, Sato M, Kakugawa Y, Nomura E, Hayashi K, Nakamura Y, Nagata T, Otsuka T, Katakura R, Yamashita Y, Sato M, Tanuma N, Shima H. Novel function of MKP-5/DUPS10, a phosphatase of stress-activated kinases, on ERK-dependent gene expression, and upregulation of its gene expression in colon carcinomas. Oncol Rep 2012, 28:931-936.
33. Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, Sun P, Huang S. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 2004, 64:4209-4217. 10.1158/0008-5472.CAN-04-0060, 15205333.
34. Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012, 92:1619-1649. 10.1152/physrev.00046.2011, 23073628.